Medication use before and after hip fracture: A population-based cohort and case-control study

Drugs and Aging

Volumn 31, Issue 7, 2014, Pages 547-553

  Rossini, Maurizio ^a   Viapiana, Ombretta ^a   Adami, Silvano ^a   Idolazzi, Luca ^a   Buda, Stefano ^b   Veronesi, Chiara ^b   Degli Esposti, Luca ^b   Gatti, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Economics and Outcomes Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM DERIVATIVE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; RESPIRATORY TRACT AGENT; THIAZIDE DIURETIC AGENT; VITAMIN D DERIVATIVE;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POLYPHARMACY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; CASE CONTROL STUDY; DRUG UTILIZATION; HIP FRACTURES; ITALY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HIP FRACTURES; HUMANS; ITALY; POLYPHARMACY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84903757152     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0184-2     Document Type: Article

References (68)

1. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.
2. Rossini M, Piscitelli P, Fitto F, et al. Incidence and socioeconomic burden of hip fractures in Italy. Reumatismo. 2005;57:97-102. (Pubitemid 41557290)
3. Piscitelli P, Iolascon G, Gimigliano F, et al. Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int. 2007;18:211-9. (Pubitemid 46090225)
4. Stevens JA, Anne Rudd R. Declining hip fracture rates in the United States. Age Ageing. 2010;39:500-3.
5. Piscitelli P, Gimigliano F, Gatto S, et al. Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int. 2010;21:1323-30.
6. Kanis JA, Oden A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239-56.
7. Oden A, McCloskey EV, Johansson H, et al. Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int. 2013;92:42-9.
8. Wilkin TJ, Devendra D. Bone densitometry is not a good predictor of hip fracture. BMJ. 2001;323:795-9. (Pubitemid 32946771)
9. Kaptoge S, Benevolenskaya LI, Bhalla AK, et al. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone. 2005;36:387-98. (Pubitemid 40403837)
10. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis J Clin Endocrinol Metab. 2005;90:2787-93. (Pubitemid 40686325)
11. Edwards MH, Jameson K, Denison H, et al. Clinically risk factors, bone density and fall history in the prediction of incident fracture among men and women. Bone. 2013;52:541-7.
12. Wei TS, Hu CH, Wang SH, et al. Fall characteristics, functional mobility and bone mineral density as risk factors of hip fracture in the community-dwelling ambulatory elderly. Osteoporos Int. 2001;12:1050-5.
13. Norton R, Campbell J, Lee-Joe T, et al. Circumstances of falls resulting in hip fractures among older people. J Am Geriatr Soc. 1997;45:1108-12. (Pubitemid 27377559)
14. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9. (Pubitemid 40897454)
15. Dennison EM, Compston JE, Flahive J, et al. Effect of co-morbidities on fracture risk: findings fromthe Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2012;50:1288-93.
16. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ. 2003;327:712.
17. Leveille SG, Jones RN, Kiely DK, et al. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA. 2009;302:2214-21.
18. Vestergaard R, Rejnmark L, Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest. 2007;132:1599-607. (Pubitemid 350156018)
19. Prieto-Alhambra D, Nogues X, Javaid MK, et al. An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis. 2013;72:911-7.
20. Janghorbani M, Feskanich D, Willett WC, et al. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care. 2006;29:1573-8. (Pubitemid 44127583)
21. Cumming RG, Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust. 1993;158:414-7. (Pubitemid 23096353)
22. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17:825-37. (Pubitemid 37082985)
23. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc. 1999;47:40-50. (Pubitemid 29044265)
24. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47:30-9. (Pubitemid 29044264)
25. Barrett-Connor E, Weiss TW, McHorney CA, et al. Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int. 2009;20:715-22.
26. Evans JG. Drugs and falls in later life. Lancet. 2003;361:448. (Pubitemid 36173707)
27. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf. 2002;11:97-104. (Pubitemid 34464329)
28. Woolcoot JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 classes on falls in elderly persons. Arch Intern Med. 2009;169:1952-60.
29. Darowsky A, Chambers SACF, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26:381-94.
30. van den Brand MW, Pouwels S, Samson MM, et al. Use of antidepressants and the risk of fracture of the hip or femur. Osteoporos Int. 2009;20:1705-13.
31. Carbone LD, Johnson KC, Bush AJ, et al. Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med. 2009;169:132-40.
32. Pouwels S, van Staa TP, Egberts AC, et al. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20:1499-506.
33. Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res. 2010;25:873-81.
34. Riche DM. Travis King S. Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy. 2010;30:716-27.
35. Pouwels S, Lalmohamed A, van Staa T, et al. Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab. 2010;95:1924-31.
36. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22:903-10.
37. Solomon DH, Mogun H, Garneau K, et al. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res. 2011;26:1561-7.
38. Yang S, Nguyen ND, Center JR, et al. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011;48:451-5.
39. Kwok CS, Yeong JKY, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768-76.
40. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171:998-1004.
41. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int. 2011;88:476-84.
42. Miller M, Stürmer T, Azrael D, et al. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011;59:430-8.
43. Arbouw ME, Movig KL, van Staa TP, et al. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int. 2011;22:2197-204.
44. Wu Q, Qu W, Crowell MD, et al. Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. J Bone Miner Res. 2013;28:753-63.
45. Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int. 2012;23:365-75.
46. Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res. 2012;27:1186-95.
47. Rabenda V, Bruyère O, Reginster JY. Risk of non vertebral fractures among elderly postmenopausal women using antidepressants. Bone. 2012;51:674-9.
48. Vestergaard P, Preto-Alhambra D, Javaid MK, et al. Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int. 2013;24:671-80.
49. Khong TP, de Vries F, Goldenberg JS, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int. 2012;91:24-31.
50. Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9:257-67.
51. Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24:1161-8.
52. Vestergaard P, Hermann P, Jensen JE, et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23:1255-65.
53. Williams LJ, Pasco JA, Henry MJ, et al. Paracetamol (acetaminophen) use, fracture and bone mineral density. Bone. 2011;48:1277-81.
54. Degli Esposti L, Adami S, Iolascon G, et al. Il costo delle fratture da osteoporosi in Italia. Risultati dello studio BLOCK (Bone Loss and Osteoporosis: Cost-of-illness Knowledge). Farmeconomia e Percorsi Terapeutici. 2011;12:89-95.
55. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther. 1997;19:346-66. (Pubitemid 27239651)
56. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcome research and pharmacoeconomic analyses. Pharmacoeconomics. 1999;16:1-8. (Pubitemid 29330467)
57. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17:123-32.
58. Cameron ID, Chen JS, March LM, et al. Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J Bone Miner Res. 2010;25:866-72.
59. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330-8. (Pubitemid 41532085)
60. Tang X, Liu G, Kang J, et al. Obesity and risk of hip fracture in adults: a meta-analysis of prospective cohort studies. PLoS One. 2013;8:e55077.
61. Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int. 2009;20:299-307.
62. Leslie WD, Giangregorio LM, Yogendran M, et al. A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving. Osteoporos Int. 2012;23:1623-9.
63. Adami S, Bertoldo F, Brandi ML, et al. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo. 2009;61:260-84.
64. van Helden S, Cals J, Kessels F, et al. Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int. 2006;17:348-54.
65. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297:387-94. (Pubitemid 46155800)
66. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18:25-34. (Pubitemid 44885493)
67. Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009;44:758-65.
68. Kragh A, Elmstahl S, Atroshi I. Older adults' medication use 6 months before and after hip fracture: a population-based cohort study. J Am Geriatr Soc. 2011;59:863-8.